Shuttle Pharmaceuticals Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) on May 3, 2023, reporting an event that occurred on May 1, 2023. The Company is a Delaware corporation and an emerging growth company.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a one-time executive compensation payment.
Material Changes
The material event reported is the award of a $112,000 annual bonus to Chief Executive Officer Dr. Anatoly Dritschilo for fiscal year 2022. This payment was made in accordance with the Board's recommendation and the CEO's Employment Agreement, reflecting the achievement of certain operational and financial results.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies. It strictly addresses the compensatory arrangement for the CEO based on past performance.
Key Facts for Investor Verification
- Executive Compensation: CEO Dr. Anatoly Dritschilo received a $112,000 bonus for FY 2022.
- Performance Criteria: The bonus was awarded based on the Company's achievement of specific operational and financial results defined in the CEO's Employment Agreement.
- Source Document: The full terms of the Employment Agreement are referenced in Exhibit 10.12 of the Company's Form S-1 Registration Statement (File No. 333-265429) filed on June 3, 2022.
- Financial Data: No other financial data or operational metrics are disclosed in this specific filing.